4.5 Article

Continuous electrodermal activity as a potential novel neurophysiological biomarker of prognosis after cardiac arrest - A pilot study

Journal

RESUSCITATION
Volume 93, Issue -, Pages 128-135

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.resuscitation.2015.06.006

Keywords

Therapeutic hypothermia; Anoxic brain injury; Electrodermal activity; Prognosis; Electroencephalography; Cardiac arrest

Funding

  1. Swiss National Science Foundation [P2GEP3_148510]
  2. Gottfried und Julia Bangerter-Rhyner Foundation
  3. American Epilepsy Society
  4. AstraZeneca
  5. Bristol-Myers Squibb
  6. Daichi-Sankyo
  7. GlaxoSmithKline
  8. Johnson and Johnson
  9. Bayer Healthcare
  10. Gilead
  11. Eisai
  12. Merck
  13. Lexicon
  14. Arena
  15. St. Jude's Medical
  16. Boston Clinical Research Institute
  17. University of Calgary
  18. Forest Pharmaceuticals
  19. UCB, Inc.
  20. Duke Clinical Research Institute
  21. Sunovion, Inc.
  22. Swiss National Science Foundation (SNF) [P2GEP3_148510] Funding Source: Swiss National Science Foundation (SNF)

Ask authors/readers for more resources

Aims: Neurological outcome prognosis remains challenging in patients undergoing therapeutic hypothermia (TH) after cardiac resuscitation. Technological advances allow for a novel wrist-worn device to continuously record electrodermal activity (EDA), a measure of pure sympathetic activity. Methods: A prospective cohort study was performed to determine the yield of continuous EDA in patients treated with TH for coma after cardiac arrest during hypothermia and normothermia. Association between EDA parameters (event-related and nonspecific electrodermal responses (ER-EDR, NS-EDR)) and outcome measures (cerebral performance category [CPC]) (Full Outline in UnResponsivenss (FOUR) score) were assessed. Results: Eighteen patients were enrolled. Total number of EDR (66.4 vs 12.0/24 h, p = 0.02), ER-EDR (39.5 vs 11.2/24 h, p = 0.009), median amplitude change of all EDR (0.08 vs 0.03 mu SI, p = 0.03) and ER-EDR (0.14 vs 0.05 mu SI, p = 0.025) were higher in patients with favorable (CPC 1-2) versus poor outcome (CPC 3-5) during hypothermia. Greater differences in EDA parameters were observed during hypothermia than normothermia. The FOUR score was correlated to the number of all EDR and median amplitudes. Conclusions: Continuous EDA potentially opens a new avenue for autonomic function monitoring in neurocritically ill patients. It is feasible in the ICU setting, even during hypothermic states. As a measure of a complete neurophysiological circuit, it may be a novel neurophysiologic biomarker of outcome after cardiac resuscitation. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available